Trial in Patients With Relapsed Ovarian Cancer

Exclusion Criteria

• •1. Subjects using immunosuppressive medications within 14 days.
• •2. Immunodeficiency or organ transplant
• •3. Live vaccines within 28 days prior to the first dose.
• •4. Major surgery within 28 days prior to the first dose.
• •5. Ovarian sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial can-cers.
• •6. Cancer therapies (chemotherapy, radiotherapy, surgery, immunotherapy, biologic or hormonal therapy) within 28 days prior to the first dose.
• •7. Concurrent treatment with an investigational agent or participation in another clinical trial.
• •9. Active infection including tuberculosis
• •10. History of a cerebral vascular accident, transient ischemic attack or subarachnoid hemorrhage within the past 6 months.
• •11. History of clinically significant hemorrhage in the past 3 months.
• •12. Untreated CNS disease, leptomeningeal disease or cord compression. Subjects with treated dis-ease should have at least 4 weeks of neurologic and radiographic stability and be off steroids for 14 days.
• •13. Significant cardiovascular disease's.
• •14. Persistance of clinically relevant therapy related toxicity from previous anticancer therapy (any grade 3-4 toxicity or grade ≥2 neuropathy).
• •15. Known hypersensitivity to the trial drugs, or to their excipients.
• •16. Has had prior exposure to IMPs, or any other immunotherapy.
• •17. Active or prior documented autoimmune or inflammatory disorders
• •18. For cohorts B and C: Medical condition requiring current systemic anticoagulation, or a history of congenital hypercoagulable condition. Subjects taking aspirin at doses \< 325 mg per day are eli-gible provided that prothrombin time is within the institutional range of normal. Use of local anti-coagulation for port maintenance is permitted